Adjuvant Capital
VC Fund
New York, United States
Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $300M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Adjuvant Capital invests in
Stages Adjuvant Capital invests in
Countries Adjuvant Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Glenn Rockman
|
|||
Michael Chang
|
|||
Charlie Petty
|
|||
Jenny Yip
|
|||
Investment Focus
Industry
- Biotechnology 18 (47%)
- Health Care 12 (32%)
- Medical 6 (16%)
- Biopharma 4 (11%)
- Life Science 3 (8%)
Stage
- Series B 9 (24%)
- Series A 8 (21%)
- Series C 5 (13%)
- Series D 3 (8%)
- Funding Round 2 (5%)
Country
- United States 11 (29%)
- Switzerland 2 (5%)
- China 1 (3%)
- Austria 1 (3%)
- Belgium 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Glenn Rockman
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 9 | Find email | |
|
Michael Chang
Principal
|
Principal | Total investments: 1 | Find email | |
|
Charlie Petty
Principal
|
Principal | Total investments: 15 | Find email | |
|
Jenny Yip
Managing Partner
|
Managing Partner | Total investments: 7 | Find email | |
Kabeer Aziz
Principal
|
Principal | Total investments: 6 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VitriVax
|
VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. | $17.3M / Series B / Oct 22, 2025 | |
|
VitriVax
|
VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. | $17.3M / Series B / Oct 22, 2025 | |
Curevo
|
Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $110M / Series B / Mar 17, 2025 | |
LimmaTech Biologics
|
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $3M / Series A / Feb 01, 2024 | |
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M / Series C / Nov 02, 2023 | |
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M / Oct 11, 2023 | |
|
LimmaTech Biologics
|
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $36.5M / Series A / Oct 09, 2023 | |
Antiva Biosciences
|
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco. | $53M / Series E / Apr 27, 2023 | |
Codagenix
|
Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $25M / Series B / Feb 15, 2023 | |
|
Codagenix
|
Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $25M / Series B / Feb 15, 2023 | |
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adjuvant Capital invest in?
Adjuvant Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Adjuvant Capital?
Public channels for Adjuvant Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Adjuvant Capital?
The team at Adjuvant Capital includes Glenn Rockman (Founder and Managing Partner), Michael Chang (Principal) and Charlie Petty (Principal), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
